{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:43:49Z","timestamp":1775328229502,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"DOI":"10.7759\/cureus.78865","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T22:22:36Z","timestamp":1739312556000},"source":"Crossref","is-referenced-by-count":2,"title":["A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease"],"prefix":"10.7759","author":[{"given":"Shoichi","family":"Fukui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawana","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Katsube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiko","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::aid-cncr2820090430>3.0.co;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman B","year":"1956","unstructured":"Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956, 9:822-30. 10.1002\/1097-0142(195607\/08)9:4&lt;822::aid-cncr2820090430&gt;3.0.co;2-4","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum DC","year":"2014","unstructured":"Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014, 123:2924-33. 10.1182\/blood-2013-12-545087","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy","volume":"6","author":"Mukherjee S","year":"2022","unstructured":"Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022, 6:359-67. 10.1182\/bloodadvances.2021004441","journal-title":"Blood Adv"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1366093","article-title":"Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan","volume":"28","author":"Fujimoto S","year":"2018","unstructured":"Fujimoto S, Koga T, Kawakami A, et al.. Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan. Mod Rheumatol. 2018, 28:161-7. 10.1080\/14397595.2017.1366093","journal-title":"Mod Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki K","year":"1989","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N, et al.. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease. Blood. 1989, 74:1360-7. 10.1182\/blood.V74.4.1360.1360","journal-title":"Blood"},{"key":"ref6","article-title":"Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy","volume":"8","author":"van Rhee F","year":"2010","unstructured":"van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010, 8:486-98.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto N","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, et al.. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005, 106:2627-32. 10.1182\/blood-2004-12-4602","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease","volume":"28","author":"van Rhee F","year":"2010","unstructured":"van Rhee F, Fayad L, Voorhees P, et al.. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010, 28:3701-8. 10.1200\/JCO.2009.27.2377","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Van Rhee F","year":"2014","unstructured":"Van Rhee F, Wong RS, Munshi N, et al.. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014, 15:966-74. 10.1016\/S1470-2045(14)70319-5","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee F","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, et al.. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018, 132:2115-24. 10.1182\/blood-2018-07-862334","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea JJ","year":"2015","unstructured":"O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015, 66:311-28. 10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino AV","year":"2017","unstructured":"Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017, 18:374-84. 10.1038\/ni.3691","journal-title":"Nat Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson SK","year":"2021","unstructured":"Pierson SK, Shenoy S, Oromendia AB, et al.. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021, 5:3445-56. 10.1182\/bloodadvances.2020004016","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese MC","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, et al.. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019, 322:315-25. 10.1001\/jama.2019.9055","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey L","year":"2013","unstructured":"Van Rompaey L, Galien R, van der Aar EM, et al.. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013, 191:3568-77. 10.4049\/jimmunol.1201348","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop KL","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017, 13:234-43. 10.1038\/nrrheum.2017.23","journal-title":"Nat Rev Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves PG","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021, 80:865-75. 10.1136\/annrheumdis-2020-219012","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman's disease: a systematic literature review","volume":"3","author":"Liu AY","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, et al.. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016, 3:163-75. 10.1016\/S2352-3026(16)00006-5","journal-title":"Lancet Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura Y","year":"2021","unstructured":"Nishimura Y, Fajgenbaum DC, Pierson SK, et al.. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021, 96:1241-52. 10.1002\/ajh.26292","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00096-1","article-title":"Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey","volume":"51","author":"Fukuhara S","year":"1998","unstructured":"Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998, 51:1045-53. 10.1016\/S0895-4356(98)00096-1","journal-title":"J Clin Epidemiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan BG","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EVJ, et al.. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021, 397:2372-84. 10.1016\/S0140-6736(21)00666-8","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead552","article-title":"Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","volume":"63","author":"K\u00e4llmark H","year":"2024","unstructured":"K\u00e4llmark H, Bergstr\u00f6m T, Nagel J, Gullstrand B, Einarsson JT, Bengtsson AA, Kapetanovic MC. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford). 2024, 63:2024-33. 10.1093\/rheumatology\/kead552","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek S","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al.. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010, 363:1117-27. 10.1056\/NEJMoa1002028","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29261","article-title":"Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series","volume":"68","author":"Lust H","year":"2021","unstructured":"Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series. Pediatr Blood Cancer. 2021, 68:e29261. 10.1002\/pbc.29261","journal-title":"Pediatr Blood Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032200","article-title":"Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report","volume":"101","author":"Kakutani T","year":"2022","unstructured":"Kakutani T, Nunokawa T, Chinen N, Tamai Y. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report. Medicine (Baltimore). 2022, 101:e32200. 10.1097\/MD.0000000000032200","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2024.2023.0477","article-title":"Ruxolitinib for the treatment of refractory idiopathic multicentric Castleman disease: a case report","volume":"41","author":"Gao YH","year":"2024","unstructured":"Gao YH, Duan MH, Li J, Zhang L. Ruxolitinib for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Turk J Haematol. 2024, 41:61-3. 10.4274\/tjh.galenos.2024.2023.0477","journal-title":"Turk J Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336728-a-phase-ib-investigator-initiated-trial-of-filgotinib-in-patients-with-idiopathic-multicentric-castleman-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T22:22:37Z","timestamp":1739312557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336728-a-phase-ib-investigator-initiated-trial-of-filgotinib-in-patients-with-idiopathic-multicentric-castleman-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.78865","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}